Insider Selling: Natera, Inc. (NASDAQ:NTRA) COO Sells 577 Shares of Stock

Natera, Inc. (NASDAQ:NTRAGet Rating) COO Robert Alan Schueren sold 577 shares of the business’s stock in a transaction on Friday, April 22nd. The stock was sold at an average price of $36.14, for a total value of $20,852.78. Following the transaction, the chief operating officer now directly owns 3,919 shares of the company’s stock, valued at approximately $141,632.66. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Robert Alan Schueren also recently made the following trade(s):

  • On Friday, April 8th, Robert Alan Schueren sold 1,999 shares of Natera stock. The stock was sold at an average price of $41.91, for a total value of $83,778.09.
  • On Monday, March 28th, Robert Alan Schueren sold 1,382 shares of Natera stock. The shares were sold at an average price of $39.63, for a total transaction of $54,768.66.

Shares of NTRA stock traded up $3.38 on Monday, hitting $39.67. The stock had a trading volume of 1,162,442 shares, compared to its average volume of 2,388,439. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of -7.67 and a beta of 1.20. The company has a debt-to-equity ratio of 0.43, a current ratio of 4.99 and a quick ratio of 4.87. The business has a 50 day moving average of $46.49 and a 200 day moving average of $75.63. Natera, Inc. has a 12-month low of $26.10 and a 12-month high of $129.09.

Natera (NASDAQ:NTRAGet Rating) last released its earnings results on Thursday, February 24th. The medical research company reported ($1.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.24) by ($0.24). The business had revenue of $173.00 million during the quarter, compared to the consensus estimate of $168.59 million. Natera had a negative net margin of 75.43% and a negative return on equity of 90.55%. The business’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the company earned ($0.89) earnings per share. As a group, research analysts expect that Natera, Inc. will post -6.05 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of NTRA. Marshall Wace LLP bought a new stake in shares of Natera in the 1st quarter worth approximately $264,000. AE Wealth Management LLC bought a new stake in shares of Natera in the 3rd quarter worth approximately $203,000. Victory Capital Management Inc. raised its holdings in shares of Natera by 1.0% in the 3rd quarter. Victory Capital Management Inc. now owns 51,865 shares of the medical research company’s stock worth $5,780,000 after purchasing an additional 496 shares during the period. New York State Common Retirement Fund increased its holdings in Natera by 4.4% in the 3rd quarter. New York State Common Retirement Fund now owns 109,626 shares of the medical research company’s stock worth $12,217,000 after acquiring an additional 4,590 shares during the last quarter. Finally, Segall Bryant & Hamill LLC increased its holdings in Natera by 2.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 86,809 shares of the medical research company’s stock worth $9,673,000 after acquiring an additional 2,248 shares during the last quarter.

Several equities research analysts recently issued reports on NTRA shares. BTIG Research decreased their price target on shares of Natera from $125.00 to $100.00 in a report on Thursday, March 10th. Stephens began coverage on Natera in a research report on Monday. They issued an “overweight” rating and a $54.00 target price for the company. The Goldman Sachs Group dropped their price objective on shares of Natera from $90.00 to $80.00 and set a “buy” rating for the company in a report on Tuesday, April 19th. Wells Fargo & Company cut their target price on Natera from $135.00 to $100.00 in a report on Monday, January 24th. Finally, Piper Sandler raised their price target on shares of Natera from $70.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, April 13th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $110.54.

Natera Company Profile (Get Rating)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Featured Stories

Insider Buying and Selling by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.